LEGEND BIOTECH CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 45.3 USD | +1.98% |
|
-1.93% | -24.71% |
| 23/04 | Genscript Biotech Unit Gets Approval for Blood Cancer Drug by European Commission | MT |
| 22/04 | Legend Biotech's Carvykti Gets European Commission Approval for Treatment of Blood Cancer | MT |
Chart calendar Legend Biotech Corporation
985a32c5cbcb03db42800.lE0y7azZ0z8eyVMUsop1wKI95ziQAaFO5Hu5_0eRr0U.-SBlitqTu1tThiJNweEGjeUOjmCgM9AGlSTysTD2nim5H0qUxJa0WzP5IA~871ce5dd0deccde15df6903316ed1e68
Upcoming events on Legend Biotech Corporation
Past events on Legend Biotech Corporation
| 11/03/2024 05:30 pm | Q4 2023 Earnings Call |
| 11/03/2024 04:30 pm | Q4 2023 Earnings Release |
| 10/01/2024 03:45 am | JPMorgan Healthcare Conference |
| 12/12/2023 07:30 am | American Society of Hematology Meeting - Abstract #4866 |
| 12/12/2023 07:30 am | American Society of Hematology Meeting - Abstract #5083 |
| 12/12/2023 06:00 am | American Society of Hematology Meeting - Abstract #1021 |
| 12/12/2023 06:00 am | American Society of Hematology Meeting - Abstract #1063 |
| 11/12/2023 07:30 am | American Society of Hematology Meeting - Abstract #3501 |
| 10/12/2023 07:00 am | American Society of Hematology Meeting - Abstract #2141 |
| 10/12/2023 07:00 am | American Society of Hematology Meeting - Abstract #2099 |
| 20/11/2023 06:30 pm | Q3 2023 Earnings Call |
| 20/11/2023 04:30 pm | Q3 2023 Earnings Release |
| 21/09/2023 07:00 pm | Annual General Meeting |
| 15/08/2023 05:30 pm | Q2 2023 Earnings Call |
| 15/08/2023 03:30 pm | Q2 2023 Earnings Release |
| 14/06/2023 08:30 pm | Goldman Sachs Global Healthcare Conference |
| 11/06/2023 03:30 pm | European Hematology Association Hybrid Congress - Abstract #S202 |
| 10/06/2023 06:15 pm | European Hematology Association Hybrid Congress - Abstract #S100 |
| 09/06/2023 09:30 pm | European Hematology Association Hybrid Congress - Abstract #P922 |
| 09/06/2023 09:30 pm | European Hematology Association Hybrid Congress - Abstract #P874 |
Annual results
| Fiscal Period | December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 75,7 51,5 46.91% | 89,8 66,9 34.16% | 117 132 -11.08% | 285 296 -3.82% | 585 |
|
EBITDA Million USD | Released Forecast Spread | -221 -201 -9.63% | -361 -274 -31.38% | -443 -305 -45.35% | -392 -420 6.65% | -320 |
|
EBIT Million USD | Released Forecast Spread | -229 -216 -5.91% | -373 -335 -11.2% | -456 -424 -7.4% | -413 -458 9.85% | -335 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -308 -329 6.5% | -386 -355 -8.74% | -446 -437 -1.97% | -520 -487 -6.75% | -317 |
|
Net income Million USD | Released Forecast Spread | -303 -325 6.69% | -386 -341 -13.32% | -446 -437 -2.06% | -518 -482 -7.55% | -316 |
|
EPS USD | Released Forecast Spread | -1,28 -1,38 7.16% | -1,37 -1,78 22.93% | -1,40 -1,38 -1.24% | -1,47 -1,65 10.96% | -1,08 |
| Announcement Date | 18/03/21 | 18/03/22 | 30/03/23 | 11/03/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 39,0 14,2 174.23% | 40,8 16,7 144.96% | 12,0 37,2 -67.81% | 27,7 | 31,3 | 36,3 39,8 -8.76% | 73,3 56,2 30.39% | 96,0 99,5 -3.51% | 79,5 95,7 -16.93% | 144 | 125 | 132 | 179 | 179 |
|
EBITDA Million USD | Released Forecast Spread | -114 -117 2.43% | -116 -74,4 -55.99% | -85,0 | -80,6 | -160 | -53,6 -132 59.36% | -63,9 | -121 | -108 | -93,5 | -77,2 | |||
|
EBIT Million USD | Released Forecast Spread | -117 -103 -14.12% | -76,0 -137 44.38% | -126 -90,7 -38.42% | -110 | -132 | -107 -155 31.2% | -104 -140 25.56% | -56,8 -122 53.37% | -141 -124 -13.65% | -60,4 | -87,0 | -101 | -91,5 | -87,6 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -88,3 -102 13.73% | -41,1 -137 69.93% | -193 -121 -59.16% | -113 | -135 | -112 -155 27.94% | -199 -130 -53.17% | -62,5 -109 42.44% | -147 -122 -19.94% | -69,3 | -90,7 | -98,1 | -84,6 | -91,6 |
|
Net income Million USD | Released Forecast Spread | -88,3 -98,2 10.04% | -41,1 -137 69.93% | -193 -121 -59.29% | -113 | -135 | -112 -153 26.61% | -199 -130 -53.33% | -62,2 -109 42.75% | -145 -112 -29.27% | -69,0 | -90,5 | -97,7 | -83,8 | -91,8 |
|
EPS USD | Released Forecast Spread | -0,30 -0,44 31.82% | -0,13 -0,49 73.47% | -0,62 -0,39 -58.71% | -0,35 | -0,42 | -0,34 -0,45 25.03% | -0,57 -0,37 -52.87% | -0,17 -0,31 44.39% | -0,40 -0,30 -31.35% | -0,18 | -0,28 | -0,29 | -0,24 | -0,25 |
| Announcement Date | 18/03/22 | 01/06/22 | 17/02/23 | - | - | 18/05/23 | 15/08/23 | 20/11/23 | 11/03/24 | - | - | - | - | - |
More events
Past sector events for Legend Biotech Corporation
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- LEGN Stock
- Calendar Legend Biotech Corporation
